Adriamycin and mitomycin C: Possible synergistic cardiotoxicity

A. U. Buzdar; S. S. Legha; C. K. Tashima; G. N. Hortobagyi; H. Y. Yap; A. N. Krutchik; M. A. Luna; G. R. Blumenschein

Adriamycin and mitomycin C: Possible synergistic cardiotoxicity

A. U. Buzdar, S. S. Legha, C. K. Tashima, G. N. Hortobagyi, H. Y. Yap, A. N. Krutchik, M. A. Luna, G. R. Blumenschein

Research output: Contribution to journal › Article › peer-review

Abstract

91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

Original language	English (US)
Pages (from-to)	1005-1008
Number of pages	4
Journal	Cancer Treatment Reports
Volume	62
Issue number	7
State	Published - Dec 1 1978
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{3e2defa9518d4fcd9ae308101eaf6183,

title = "Adriamycin and mitomycin C: Possible synergistic cardiotoxicity",

abstract = "91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.",

author = "Buzdar, {A. U.} and Legha, {S. S.} and Tashima, {C. K.} and Hortobagyi, {G. N.} and Yap, {H. Y.} and Krutchik, {A. N.} and Luna, {M. A.} and Blumenschein, {G. R.}",

year = "1978",

month = dec,

day = "1",

language = "English (US)",

volume = "62",

pages = "1005--1008",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Adriamycin and mitomycin C

T2 - Possible synergistic cardiotoxicity

AU - Buzdar, A. U.

AU - Legha, S. S.

AU - Tashima, C. K.

AU - Hortobagyi, G. N.

AU - Yap, H. Y.

AU - Krutchik, A. N.

AU - Luna, M. A.

AU - Blumenschein, G. R.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - 91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

AB - 91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

UR - http://www.scopus.com/inward/record.url?scp=0018144412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018144412&partnerID=8YFLogxK

M3 - Article

C2 - 688243

AN - SCOPUS:0018144412

SN - 0361-5960

VL - 62

SP - 1005

EP - 1008

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 7

ER -

Adriamycin and mitomycin C: Possible synergistic cardiotoxicity

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this